{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:17:51Z","timestamp":1791404271704,"version":"4.3.3"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>New drugs targeting antimicrobial resistant pathogens, including <jats:italic>Pseudomonas aeruginosa<\/jats:italic>, have been challenging to evaluate in clinical trials, particularly for the non-ventilated hospital-acquired pneumonia and ventilator-associated pneumonia indications. Development of new antibacterial drugs is facilitated by preclinical animal models that could predict clinical efficacy in patients with these infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We report here an FDA-funded study to develop a rabbit model of non-ventilated pneumonia with <jats:italic>Pseudomonas aeruginosa<\/jats:italic> by determining the extent to which the natural history of animal disease reproduced human pathophysiology and conducting validation studies to evaluate whether humanized dosing regimens of two antibiotics, meropenem and tobramycin, can halt or reverse disease progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In a rabbit model of non-ventilated pneumonia, endobronchial challenge with live <jats:italic>P. aeruginosa strain<\/jats:italic> 6206, but not with UV-killed Pa6206, caused acute respiratory distress syndrome, as evidenced by acute lung inflammation, pulmonary edema, hemorrhage, severe hypoxemia, hyperlactatemia, neutropenia, thrombocytopenia, and hypoglycemia, which preceded respiratory failure and death. Pa6206 increased &amp;gt;100-fold in the lungs and then disseminated from there to infect distal organs, including spleen and kidneys. At 5\u00a0h post-infection, 67% of Pa6206-challenged rabbits had PaO<jats:sub>2<\/jats:sub> &amp;lt;60 mmHg, corresponding to a clinical cut-off when oxygen therapy would be required. When administered at 5\u00a0h post-infection, humanized dosing regimens of tobramycin and meropenem reduced mortality to 17-33%, compared to 100% for saline-treated rabbits (<jats:italic>P<\/jats:italic>&amp;lt;0.001 by log-rank tests). For meropenem which exhibits time-dependent bactericidal activity, rabbits treated with a humanized meropenem dosing regimen of 80 mg\/kg q2h for 24\u00a0h achieved 100% T&amp;gt;MIC, resulting in 75% microbiological clearance rate of Pa6206 from the lungs. For tobramycin which exhibits concentration-dependent killing, rabbits treated with a humanized tobramycin dosing regimen of 8 mg\/kg q8h for 24\u00a0h achieved C<jats:sub>max<\/jats:sub>\/MIC of 9.8 \u00b1 1.4 at 60\u00a0min post-dose, resulting in 50% lung microbiological clearance rate. In contrast, rabbits treated with a single tobramycin dose of 2.5 mg\/kg had C<jats:sub>max<\/jats:sub>\/MIC of 7.8 \u00b1 0.8 and 8% (1\/12) microbiological clearance rate, indicating that this rabbit model can detect dose-response effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The rabbit model may be used to help predict clinical efficacy of new antibacterial drugs for the treatment of non-ventilated <jats:italic>P. aeruginosa<\/jats:italic> pneumonia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2023.1297281","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T10:02:25Z","timestamp":1702288945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Development and validation of a rabbit model of Pseudomonas aeruginosa non-ventilated pneumonia for preclinical drug development"],"prefix":"10.3389","volume":"13","author":[{"given":"Emmanuelle","family":"Gras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang T. T.","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhu T. Q.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vuvi G.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen D.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam H.","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver X.","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia L. P. P.","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helvecio C. C.","family":"Povoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Gabriel","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Aguiar-Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily I.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles K.","family":"Stover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bret R.","family":"Sellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"DiGiandomenico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Valour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binh An","family":"Diep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0924-8579(02)00022-5","article-title":"Animal model pharmacokinetics and pharmacodynamics: a critical review","volume":"19","author":"Andes","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B3","doi-asserted-by":"publisher","first-page":"14736","DOI":"10.1038\/s41598-018-32938-6","article-title":"Profiling inflammatory markers in patients with pneumonia on intensive care","volume":"8","author":"Antcliffe","year":"2018","journal-title":"Sci. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJMra1003327","article-title":"Physiological approach to assessment of acid-base disturbances","volume":"371","author":"Berend","year":"2014","journal-title":"N Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01983-20","article-title":"FDA public workshop summary: advancing animal models for antibacterial drug development","volume":"65","author":"Byrne","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/CCM.0000000000000742","article-title":"Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database","volume":"43","author":"Casserly","year":"2015","journal-title":"Crit. Care Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1378\/chest.13-0062","article-title":"Impact of age and comorbidity on cause and outcome in community-acquired pneumonia","volume":"144","author":"Cilloniz","year":"2013","journal-title":"Chest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1128\/IAI.71.3.1328-1336.2003","article-title":"Experimental Pseudomonas aeruginosa keratitis in interleukin-10 gene knockout mice","volume":"71","author":"Cole","year":"2003","journal-title":"Infect. Immun."},{"key":"B9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/infdis\/jit129","article-title":"Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia","volume":"208","author":"Diep","year":"2013","journal-title":"J. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1073\/pnas.0912403107","article-title":"Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury","volume":"107","author":"Diep","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B11","doi-asserted-by":"publisher","first-page":"357ra124","DOI":"10.1126\/scitranslmed.aag1153","article-title":"IVIG-mediated protection against necrotizing pneumonia caused by MRSA","volume":"8","author":"Diep","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02456-16","article-title":"Targeting alpha toxin to mitigate its lethal toxicity in ferret and rabbit models of Staphylococcus aureus necrotizing pneumonia","volume":"61","author":"Diep","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"262ra155","DOI":"10.1126\/scitranslmed.3009655","article-title":"A multifunctional bispecific antibody protects against Pseudomonas aeruginosa","volume":"6","author":"DiGiandomenico","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1128\/iai.60.7.2835-2842.1992","article-title":"Interleukin-8 in sepsis: relation to shock and inflammatory mediators","volume":"60","author":"Hack","year":"1992","journal-title":"Infect. Immun."},{"key":"B15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijantimicag.2014.09.009","article-title":"Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration","volume":"45","author":"Jamal","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12890-019-0803-0","article-title":"Prognostic values of the Berlin definition criteria, blood lactate level, and fibroproliferative changes on high-resolution computed tomography in ARDS patients","volume":"19","author":"Kamo","year":"2019","journal-title":"BMC Pulm. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1128\/AAC.42.7.1842","article-title":"Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms","volume":"42","author":"Kashuba","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s10096-016-2703-z","article-title":"Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP\/CAP study","volume":"36","author":"Koulenti","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02565-17","article-title":"MEDI3902 Correlates of Protection against Severe Pseudomonas aeruginosa Pneumonia in a Rabbit Acute Pneumonia Model","volume":"62","author":"Le","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00710-19","article-title":"Treatment efficacy of MEDI3902 in Pseudomonas aeruginosa bloodstream infection and acute pneumonia rabbit models","volume":"63","author":"Le","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/INF.0000000000000024","article-title":"Clinical and laboratory factors that predict death in very low birth weight infants presenting with late-onset sepsis","volume":"33","author":"Levit","year":"2014","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1128\/AAC.00294-06","article-title":"Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections","volume":"51","author":"Li","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1592\/phco.26.9.1320","article-title":"Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists","volume":"26","author":"Lodise","year":"2006","journal-title":"Pharmacotherapy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1172\/JCI113540","article-title":"Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits","volume":"81","author":"Mathison","year":"1988","journal-title":"J. Clin. Invest."},{"key":"B26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02724-20","article-title":"Pseudomonas aeruginosa ventilator-associated pneumonia rabbit model for preclinical drug development","volume":"65","author":"Nguyen","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1086\/590064","article-title":"Pharmacokinetic and pharmacodynamic properties of meropenem","volume":"47","author":"Nicolau","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1258\/002367771781006483","article-title":"Pseudomonas aeruginosa in rabbit fur","volume":"5","author":"O'Donoghue","year":"1971","journal-title":"Lab. Anim."},{"key":"B30","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1183\/09031936.04.00119503","article-title":"Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor","volume":"24","author":"Paganin","year":"2004","journal-title":"Eur. Respir. J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/1471-2334-10-181","article-title":"Altered blood glucose concentration is associated with risk of death among patients with community-acquired Gram-negative rod bacteremia","volume":"10","author":"Peralta","year":"2010","journal-title":"BMC Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1128\/IAI.71.3.1453-1461.2003","article-title":"Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant","volume":"71","author":"Priebe","year":"2003","journal-title":"Infect. Immun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/jac\/dkp139","article-title":"Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution","volume":"64","author":"Roberts","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1128\/iai.6.2.149-155.1972","article-title":"Effect of vincristine sulfate on Pseudomonas infections in monkeys","volume":"6","author":"Saslaw","year":"1972","journal-title":"Infect. Immun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1172\/JCI89652","article-title":"Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature","volume":"127","author":"Thanabalasuriar","year":"2017","journal-title":"J. Clin. Invest."},{"key":"B37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S2213-2600(13)70053-5","article-title":"Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies","volume":"1","author":"Thille","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0140-6736(84)92269-4","article-title":"Transient leucopenia associated with adult respiratory distress syndrome","volume":"1","author":"Thommasen","year":"1984","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1056\/NEJMra1608077","article-title":"Acute respiratory distress syndrome","volume":"377","author":"Thompson","year":"2017","journal-title":"N Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/infdis\/jiz437","article-title":"Efficacy of Active Immunization With Attenuated alpha-Hemolysin and Panton-Valentine Leukocidin in a Rabbit Model of Staphylococcus aureus Necrotizing Pneumonia","volume":"221","author":"Tran","year":"2020","journal-title":"J. Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00316","article-title":"A comparative review of toll-like receptor 4 expression and functionality in different animal species","volume":"5","author":"Vaure","year":"2014","journal-title":"Front. Immunol."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02220-19","article-title":"Protective efficacy of monoclonal antibodies neutralizing alpha-hemolysin and bicomponent leukocidins in rabbit model of Staphylococcus aureus necrotizing pneumonia","volume":"64","author":"Vu","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02242-19","article-title":"Assessing animal models of bacterial pneumonia used in investigational new drug applications for the treatment of bacterial pneumonia","volume":"64","author":"Waack","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1086\/649557","article-title":"Resilience to bacterial infection: difference between species could be due to proteins in serum","volume":"201","author":"Warren","year":"2010","journal-title":"J. Infect. Dis."},{"key":"B45","unstructured":"Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics2017"},{"key":"B46","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs BioMed."},{"key":"B47","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/CCM.0000000000005298","article-title":"Descriptive epidemiology and outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2012-2019","volume":"50","author":"Zilberberg","year":"2022","journal-title":"Crit. Care Med."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1297281\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T10:02:28Z","timestamp":1702288948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1297281\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":47,"alternative-id":["10.3389\/fcimb.2023.1297281"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1297281","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]},"article-number":"1297281"}}